Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background The US is experiencing an STI epidemic, with more than one-half of Americans at risk of an STI infection in their lifetime. An all-time high number of STIs was reported in 2021, with the combined number of cases for gonorrhea, syphilis, and chlamydia soaring to 2.54 million. To understand STI incidence among persons with…
Background Doxycycline pre-exposure prophylaxis (doxyPrEP) has shown potential in preventing bacterial sexually transmitted infections (STIs) in gay, bisexual and other men who have sex with men (GBM). However, its impact on the microbiome is unknown. This study assessed rectal microbiome changes over 48 weeks in participants on HIV PrEP enrolled in a doxyPrEP trial. Methods…
Background Currently, there are 20.2 million girls and women living with HIV and nearly half of pregnancies are unintended. This leads to a global economic and health burden for women and as such, technologies that can prevent HIV infections and unintended pregnancies are warranted. We evaluated a long-acting (LA), injectable in-situ forming implant (ISFI) as a…
Background Young men who have sex with men (YMSM) have high HIV incidence and challenges with PrEP adherence. Point-of-care (POC) urine tenofovir (TFV) testing permits real-time objective adherence monitoring at a low cost. A prior study with PrEP-using women in Kenya demonstrated improved long-term adherence when women had motivational interviewing (MI)-informed drug-level feedback using the…
Background The highly efficacious mRNA-based COVID-19 vaccines had good uptake in Washington State and Oregon with at least 75% of the population in each state receiving at least one dose. Estimating the impact of COVID-19 vaccination campaigns has been challenging given 1) the concurrent buildup of population-level immunity from infection, primary vaccination, and booster doses,…
Background Despite high efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention, uptake is low among cisgender women in the US, especially in the South where >50% of new HIV diagnoses occur. The Ending the HIV Epidemic (EHE) initiative prioritizes 57 jurisdictions for targeted HIV prevention and treatment interventions. To identify opportunities for optimizing HIV prevention…
Background Rise of web-based dating platforms have created a “virtual vulnerable population” who do not visit traditional HIV sites, with an HIV burden 20 times higher than the national average (0.2%) highlighting the need to adapt virtual service delivery of interventions such as PrEP . Given the penetration of mobile technology in India with resource…
Background The population-level impact of HIV PrEP in the US has been limited by structural barriers to access, particularly in historically marginalized populations. Making PrEP available over the counter (OTC) on pharmacy shelves or online, without the need for a prescription, may address some of those barriers. However, it is unknown if populations likely to…
Background Publicly-funded oral HIV PrEP has been available to key populations in British Columbia (BC) through the BC Centre for Excellence in HIV/AIDS since 2018. We examined differences in characteristics of PrEP enrollees with and without subsequent HIV diagnoses. Methods We included clients with ≥1 PrEP prescription dispensed between 1-Jan-2018 and 31-Dec-2023 (follow-up to 30-Jun-2024).…
Background Consistent use of daily oral preexposure prophylaxis (PrEP) during periods of HIV risk is essential for optimal HIV protection. This study estimated and compared persistence of oral PrEP among early and more recent cohorts of PrEP users using a national pharmacy database. Methods We analyzed data from the IQVIA Real-World Data—Longitudinal Prescription Database (2017−2023) to…